morphine sulfate extended-release
GPTKB entity
Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
opioid |
| gptkbp:activeIngredient |
gptkb:morphine_sulfate
|
| gptkbp:ATCCode |
N02AA01
|
| gptkbp:brand |
gptkb:MS_Contin
gptkb:Avinza gptkb:Kadian |
| gptkbp:contraindication |
paralytic ileus
acute respiratory depression |
| gptkbp:controlledSubstanceSchedule |
gptkb:Schedule_II_(US)
|
| gptkbp:eliminatedIn |
renal
|
| gptkbp:form |
gptkb:tablet
capsule |
| gptkbp:halfLife |
15-30 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
morphine sulfate extended-release
|
| gptkbp:indication |
chronic pain
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
mu-opioid receptor agonist
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:riskFactor |
addiction
overdose |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
constipation drowsiness respiratory depression |
| gptkbp:bfsParent |
gptkb:Avinza
|
| gptkbp:bfsLayer |
7
|